drugset

drugset / Trial / NCT07070960

A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible

NCT07070960 ↗

Not yet recruiting 35 enrolled Xuzhou Medical University

NaSingle-groupOpen-labelTreatment

Summary

This is a prospective study of anti-BCMA CAR-T in transplant-ineligible patients with newly diagnosed multiple myeloma.

Timeline

Start: 2025-07-15
Primary completion: 2026-07-15
Completion: 2028-07-31

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CAR-T	Cell therapy	2 cells/kg	—

Indications